Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has been given a consensus rating of “Hold” by the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $7.30.

ACHN has been the topic of several recent analyst reports. Chardan Capital reissued a “neutral” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, September 17th. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 14th. Ladenburg Thalmann Financial Services dropped their price target on Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a research note on Tuesday, September 12th. Robert W. Baird reissued a “neutral” rating and issued a $4.00 price target (down from $5.00) on shares of Achillion Pharmaceuticals in a research note on Tuesday, September 12th. Finally, ValuEngine lowered Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Monday, September 11th.

COPYRIGHT VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of “Hold” by Brokerages” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/25/achillion-pharmaceuticals-inc-achn-given-consensus-recommendation-of-hold-by-brokerages.html.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. increased its stake in Achillion Pharmaceuticals by 3.6% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 23,130 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 800 shares during the last quarter. SG Americas Securities LLC increased its stake in Achillion Pharmaceuticals by 18.6% in the 2nd quarter. SG Americas Securities LLC now owns 26,429 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 4,144 shares during the last quarter. TradeLink Capital LLC bought a new position in Achillion Pharmaceuticals in the 2nd quarter worth about $132,000. Highbridge Capital Management LLC bought a new position in Achillion Pharmaceuticals in the 1st quarter worth about $149,000. Finally, Legal & General Group Plc increased its stake in Achillion Pharmaceuticals by 53.8% in the 2nd quarter. Legal & General Group Plc now owns 42,900 shares of the biopharmaceutical company’s stock worth $196,000 after acquiring an additional 15,000 shares during the last quarter. Institutional investors and hedge funds own 74.57% of the company’s stock.

Shares of Achillion Pharmaceuticals (ACHN) opened at 3.83 on Wednesday. The stock has a 50 day moving average price of $4.31 and a 200-day moving average price of $4.27. The company’s market capitalization is $523.79 million. Achillion Pharmaceuticals has a 52 week low of $3.15 and a 52 week high of $6.87.

Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.16). During the same period last year, the business earned ($0.14) earnings per share. Equities research analysts expect that Achillion Pharmaceuticals will post ($0.66) EPS for the current year.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Analyst Recommendations for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.